FLUIDDA’s CEO Dr. Jan De Backer will present at IPF Summit in Boston next month. Dr De Backer will discuss how using Functional Respiratory Imaging (FRI) in clinical trials has led to valuable insights into disease progression and treatment effects. Furthermore, the use of FRI, as an FDA supported drug development tool, will be discussed. FRI is a combination of CT imaging, computer-based flow simulations and artificial intelligence which provides unparalleled insights into regional lung structure and function. FRI allows researchers to assess novel drugs in a smaller cohort in a shorter timeframe thereby increasing the probability of bringing more effective drugs faster to the market.
Functional Respiratory Imaging (FRI) yields unparalleled insights into airway volumes (blue), fibrosis (green), blood vessels (red) and emphysema (black) thereby accelerating drug development
About IPF Summit:
The inaugural Idiopathic Pulmonary Fibrosis (IPF) Summit is the only event to focus solely on IPF. This unique meeting is your opportunity to join the leading minds across biopharma and academia to reduce the expansive translational gap that exists in current IPF drug development. Across 3 jam-packed days the brightest minds from the likes of Boehringer Ingelheim, Promedior, Fibrogen and many more will be sharing their insight and lessons learned to collectively enable the community to:
– Effectively translate into the clinic by better recapitulating IPF through robust in vitro and vivo models
– Define more meaningful preclinical endpoints to aid identification of novel targets and development of more effective IPF therapeutics
– Validate non-invasive biomarker and diagnostic techniques for back translation and ultimately achieve greater clinical benefit
For more information go to: http://www.globaleventslist.elsevier.com/events/2017/08/ipf-summit/